Teva Pharmaceutical is starting a global research collaboration to examine multiple pathways of neuroprotection in Huntington’s disease.
Teva Pharmaceutical Industries Ltd. recently announced the formation of a research collaboration to “create a comprehensive understanding and drive insights into neuroprotective therapeutic approaches” in Huntington’s disease, a neurodegenerative genetic disorder that affects muscle coordination and leads to cognitive decline and psychiatric problems. The current therapy for Huntington’s disease consists of symptom management. However, there are no treatment options that control, stop or reverse the progression of the disease.
According to Teva, the new cooperation will bring together researchers in the field from Canada, Germany and Singapore to name a few of the countries. The study will be coordinated in a research program developed by Dr Michael Hayden, one of the foremost experts on the disease. The main focus is the interaction between laquinimod, a neuroprotective agent currently being investigated in multiple sclerosis, and a range of molecular pathways operative in Huntington disease such as immune dysfunction in the periphery, inflammation in astrocytes and microglia and astrocyte activation in the brain.
